` EXAS (Exact Sciences Corp) vs S&P 500 Comparison - Alpha Spread

EXAS
vs
S&P 500

Over the past 12 months, EXAS has underperformed S&P 500, delivering a return of 11% compared to the S&P 500's 12% growth.

Stocks Performance
EXAS vs S&P 500

Loading

Performance Gap
EXAS vs S&P 500

Loading
EXAS
S&P 500
Difference

Performance By Year
EXAS vs S&P 500

Loading
EXAS
S&P 500
Add Stock

Competitors Performance
Exact Sciences Corp vs Peers

S&P 500
EXAS
ABBV
AMGN
GILD
VRTX
Add Stock

Exact Sciences Corp
Glance View

Economic Moat
None
Market Cap
10.6B USD
Industry
Biotechnology

Exact Sciences Corp. has crafted a compelling narrative in the realm of molecular diagnostics, primarily revolutionizing the way cancer is detected and managed. Founded with a mission to eradicate cancer's mortality through early detection, the company has carved out a prominent niche with its flagship product, Cologuard. This non-invasive, stool-based DNA screening test for colorectal cancer offers an alternative to traditional colonoscopy, making cancer screening more accessible and less intimidating. By capitalizing on advancements in genomics and leveraging sophisticated algorithmic analysis, Exact Sciences has managed to transform routine medical testing, garnering robust support from both physicians and patients. The test, approved by regulatory bodies and integrated into various insurance plans, forms the cornerstone of Exact Sciences’ revenue model, contributing significantly to its bottom line by combining upfront test fees with ongoing follow-up services. Beyond colorectal cancer, Exact Sciences is ambitiously expanding its portfolio through both internal research and strategic acquisitions. The company's vision extends to a comprehensive suite of diagnostic tools covering multiple cancer types, notably breast and liver cancer, reflecting its commitment to innovation and growth. Recent acquisitions, such as Thrive Earlier Detection and PreventionGenetics, have fortified its capabilities in early-stage cancer detection and genetic testing, positioning it well for future opportunities. This strategic expansion not only broadens its product base but also enhances recurring revenue streams through continued engagement with healthcare providers and patients. By intertwining cutting-edge science with a savvy commercial strategy, Exact Sciences is shaping the future of personalized medicine while steadily augmenting its financial health.

EXAS Intrinsic Value
41.68 USD
Overvaluation 26%
Intrinsic Value
Price
Back to Top